Medica Venture Partners

Regentis Biomaterials Ltd. is a tissue repair company specializing in the development and commercialization of biodegradable hydrogels aimed at regenerating damaged cartilage tissue. The company's primary product, GelrinC, is a hydrogel designed for the treatment of articular cartilage lesions and is currently undergoing clinical trials. GelrinC serves a range of orthopedic applications, including microfracture and autologous chondrocyte implantation procedures. The hydrogel platform, Gelrin, combines polyethylene glycol diacrylate and denatured fibrinogen, offering both the stability of synthetic materials and the bio-functionality of natural substances. Founded in 2004, Regentis Biomaterials is headquartered in Or-Akiva, Israel, with an additional office in Princeton, New Jersey. The company is committed to enhancing patient health and quality of life through innovative tissue repair solutions.

Regentis Biomaterials Ltd. is a tissue repair company specializing in the development and commercialization of biodegradable hydrogels aimed at regenerating damaged cartilage tissue. The company's primary product, GelrinC, is a hydrogel designed for the treatment of articular cartilage lesions and is currently undergoing clinical trials. GelrinC serves a range of orthopedic applications, including microfracture and autologous chondrocyte implantation procedures. The hydrogel platform, Gelrin, combines polyethylene glycol diacrylate and denatured fibrinogen, offering both the stability of synthetic materials and the bio-functionality of natural substances. Founded in 2004, Regentis Biomaterials is headquartered in Or-Akiva, Israel, with an additional office in Princeton, New Jersey. The company is committed to enhancing patient health and quality of life through innovative tissue repair solutions.

SuperDimension is a privately-held medical device company that develops and markets minimally-invasive pulmonology devices that enable the diagnosis and potentially the treatment of distal lung disease. Our product line, the i·LogicTM System, includes both capital equipment and disposables, addressing a total available market of more than 8 million patients. Driven by our mission, "To be the world leader in the diagnosis and treatment of distal lung disease," we are focused on extending the capabilities of traditional bronchoscopy tools to help diagnose previously inaccessible lung lesions at an earlier stage when they may be easier to treat.

SuperDimension is a privately-held medical device company that develops and markets minimally-invasive pulmonology devices that enable the diagnosis and potentially the treatment of distal lung disease. Our product line, the i·LogicTM System, includes both capital equipment and disposables, addressing a total available market of more than 8 million patients. Driven by our mission, "To be the world leader in the diagnosis and treatment of distal lung disease," we are focused on extending the capabilities of traditional bronchoscopy tools to help diagnose previously inaccessible lung lesions at an earlier stage when they may be easier to treat.

Regentis Biomaterials Ltd. is a tissue repair company specializing in the development and commercialization of biodegradable hydrogels aimed at regenerating damaged cartilage tissue. The company's primary product, GelrinC, is a hydrogel designed for the treatment of articular cartilage lesions and is currently undergoing clinical trials. GelrinC serves a range of orthopedic applications, including microfracture and autologous chondrocyte implantation procedures. The hydrogel platform, Gelrin, combines polyethylene glycol diacrylate and denatured fibrinogen, offering both the stability of synthetic materials and the bio-functionality of natural substances. Founded in 2004, Regentis Biomaterials is headquartered in Or-Akiva, Israel, with an additional office in Princeton, New Jersey. The company is committed to enhancing patient health and quality of life through innovative tissue repair solutions.

FlowMedica a medical device company, produces intravascular systems for implementing Targeted Renal Therapy. The company offers Benephit CV Infusion System that provides physician-specified therapeutic agents directly into the renal arteries through an infusion catheter while allowing simultaneous coronary procedures through a single vessel access site in the femoral artery; and Benephit XTMini Infusion System that allows for bilateral infusion to the kidneys in patients with smaller vascular anatomies.

InterCure Ltd. is a medical device company based in Israel that specializes in the development of innovative technology for the treatment of cardiovascular and pulmonary diseases. Established in 1994, the company has created a patented technology platform known as "Interactive Respiratory-Pacing," which underpins its product lines. InterCure's first market-ready device, RESPeRATE, is the only FDA-cleared medical device that has been clinically proven to lower high blood pressure without side effects. The company is also advancing its heart failure treatment, InTone™, which has completed phase 2a efficacy clinical trials and is awaiting regulatory approval for market launch. With a strong management team and a well-regarded Scientific Advisory Board, InterCure aims to lead the market in non-drug treatments for prevalent chronic conditions, focusing on patient-centered care.

Remon Medical Technologies is a development-stage company based in Caesarea, Israel, specializing in communication technology for medical device applications. The company has developed innovative products, including RemonCHF, a device designed to monitor the hemodynamic status of patients with congestive heart failure, and RemonAAA, which tracks pressure following endograft procedures in patients with abdominal aortic aneurysms. By focusing on miniature implants and advanced medical devices, Remon Medical Technologies aims to enhance patient monitoring and care in critical health conditions.

FlowMedica a medical device company, produces intravascular systems for implementing Targeted Renal Therapy. The company offers Benephit CV Infusion System that provides physician-specified therapeutic agents directly into the renal arteries through an infusion catheter while allowing simultaneous coronary procedures through a single vessel access site in the femoral artery; and Benephit XTMini Infusion System that allows for bilateral infusion to the kidneys in patients with smaller vascular anatomies.

Dynogen is a privately held, neuroscience-based pharmaceutical company focused on genitourinary (GU) and gastrointestinal (GI) disorders. The company is utilizing its knowledge of the nexus between neurology and GU/GI disorders, as well as its predictive in vitro and in vivo pharmacology platforms to rapidly build a pipeline of development programs. Today, Dynogen has two ongoing development programs, one for overactive bladder (OAB) and another for irritable bowel syndrome (IBS). The company will advance its OAB program into Phase IIa trials and enter the clinic with its IBS program later this year.

SuperDimension is a privately-held medical device company that develops and markets minimally-invasive pulmonology devices that enable the diagnosis and potentially the treatment of distal lung disease. Our product line, the i·LogicTM System, includes both capital equipment and disposables, addressing a total available market of more than 8 million patients. Driven by our mission, "To be the world leader in the diagnosis and treatment of distal lung disease," we are focused on extending the capabilities of traditional bronchoscopy tools to help diagnose previously inaccessible lung lesions at an earlier stage when they may be easier to treat.

As of January 27, 2004, Percutaneous Valve Technologies was acquired by Edwards Lifesciences Corp. The company develops medical devices for delivering heart valves to treat late-stage aortic stenosis. Percutaneous Valve Technologies, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.

Impella CardioSystems AG, located in Aachen, Germany, specializes in the development, manufacturing, and marketing of minimally invasive cardiovascular support systems designed for various cardiology and coronary surgery applications. The company produces intracorporeal micro blood pumps, which are utilized to support patients undergoing these medical procedures. With a robust portfolio of over 30 European and international patents protecting its innovative technology, Impella employs a team of 50 individuals. For the past two years, the company has collaborated with Accelerated Technologies, Inc., a medical device accelerator based in Hackensack, New Jersey, to enhance its growth and development in the medical device sector.

Orex Computed Radiography manufactures computerized radiography solutions. The company’s products includes Kodak Point-of-Care CR120, CR140, and CR260 that enables medical practitioners to acquire patient digital x-ray images from around the world. KODAK Point-of-Care CR-ITX 560 is a solution system that brings digital x-ray imaging directly to the patient. KODAK CR 7400 Digital Radiography is a system that delivers intraoral and extra oral images digitally. Orex Computed Radiography is an Israel-based company that was founded in 1996. The company was acquired by Kodak on January 19, 2005.

InterCure Ltd. is a medical device company based in Israel that specializes in the development of innovative technology for the treatment of cardiovascular and pulmonary diseases. Established in 1994, the company has created a patented technology platform known as "Interactive Respiratory-Pacing," which underpins its product lines. InterCure's first market-ready device, RESPeRATE, is the only FDA-cleared medical device that has been clinically proven to lower high blood pressure without side effects. The company is also advancing its heart failure treatment, InTone™, which has completed phase 2a efficacy clinical trials and is awaiting regulatory approval for market launch. With a strong management team and a well-regarded Scientific Advisory Board, InterCure aims to lead the market in non-drug treatments for prevalent chronic conditions, focusing on patient-centered care.

As of January 27, 2004, Percutaneous Valve Technologies was acquired by Edwards Lifesciences Corp. The company develops medical devices for delivering heart valves to treat late-stage aortic stenosis. Percutaneous Valve Technologies, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.